Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)
Conditions
Keywords
Long-chain Fatty Acid Oxidation Disorders (LC-FAOD), Triheptanoin
Brief summary
The primary objective of the study is to evaluate the clinical outcomes for the trigger event of patients who receive triheptanoin in the emergency Investigational New Drug (eIND) program.
Detailed description
The study is a retrospective chart review of patients in the USA with LC-FAOD who received triheptanoin via eIND request from their metabolic or treating physician before 01 September 2018. Participating study sites will provide the medical records of subjects who meet eligibility criteria, and relevant data regarding the trigger event (the reason the patient was placed on triheptanoin) and key details about hospitalizations during the study period will be extracted.
Interventions
OTHERNo Intervention
This is a non-interventional retrospective medical record review study. No study investigational product will be administered in this protocol.
Sponsors
Ultragenyx Pharmaceutical Inc
Study design
Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Inclusion criteria
* Male or female patients of any age with confirmed diagnosis of one of the LC-FAOD disorders including: mitochondrial trifunctional protein (TFP) deficiency, carnitine palmitoyltransferase deficiencies (CPT I and CPT II), very long chain acyl-CoA dehydrogenase (VLCAD) deficiency, long-chain 3-hydroxy-acyl-CoA dehydrogenase (LCHAD) deficiency, and carnitine acylcarnitine translocase (CATR) deficiency * Treatment initiation with triheptanoin was via eIND before 01 September 2018 * Treated with triheptanoin in the USA * Willing and able to provide written, signed informed consent, or where appropriate for subjects under the age of 18, or provide written assent and written informed consent by a legally authorized representative after the nature of the study has been explained and prior to any research-related procedures. To obtain and review medical records of deceased individuals, informed consent from next of kin or appropriate legal entity will be obtained, as applicable.
Exclusion criteria
* Unwilling to sign informed consent or assent to release of medical records
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Duration of Hospitalization for Trigger Event | Up to 48 Weeks Prior to and 48 Weeks After the Start of Triheptanoin Treatment |
| Duration of Important Interventions for Trigger Event | Up to 48 Weeks Prior to and 48 Weeks After the Start of Triheptanoin Treatment |
| Number of Critical Medical Assessments Related to LC-FAOD for Trigger Event | Up to 48 Weeks Prior to and 48 Weeks After the Start of Triheptanoin Treatment |
| Disposition on Discharge of Trigger Event | Up to 48 Weeks Prior to and 48 Weeks After the Start of Triheptanoin Treatment |
Secondary
| Measure | Time frame |
|---|---|
| Duration of Hospitalization for Other Major Clinical Events | Up to 48 Weeks Prior to and 48 Weeks After the Start of Triheptanoin Treatment |
| Disposition on Discharge of Other Major Clinical Events | Up to 48 Weeks Prior to and 48 Weeks After the Start of Triheptanoin Treatment |
| Number of Important Medical Interventions for Other Major Clinical Events | Up to 48 Weeks Prior to and 48 Weeks After the Start of Triheptanoin Treatment |
| Number of Critical Medical Assessments Related to LC-FAOD for Other Major Clinical Events | Up to 48 Weeks Prior to and 48 Weeks After the Start of Triheptanoin Treatment |
Countries
United States
Outcome results
None listed